氨基-(2,3-二氯-苯基)-乙酸 | 318270-11-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氨基-(2,3-二氯-苯基)-乙酸
• 英文名称: amino(2,3-dichlorophenyl)acetic acid
• 英文别名: 2-amino-2-(2,3-dichlorophenyl)acetic acid；2-azaniumyl-2-(2,3-dichlorophenyl)acetate
• CAS: 318270-11-0
• 化学式: C₈H₇Cl₂NO₂
• mdl: MFCD02662393
• 分子量: 220.055
• InChiKey: BIILIFHAKJGBSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氨基-(2,3-二氯-苯基)-乙酸 在 硼烷四氢呋喃络合物 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以91%的产率得到2-amino-2-(2,3-dichlorophenyl)ethanol
  参考文献：
  名称：

  SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF

  摘要：

  本申请涉及新的、取代的2-乙酰胺基-5-芳基-1,2,4-三唑酮，以及制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。

  公开号：

  US20100261771A1

文献信息

• SUBSTITUTED PHENYLACETATE AND PHENYLPROPANE AMIDES AND USE THEREOF
  申请人：Fürstner Chantal

  公开号：US20130231313A1

  公开（公告）日：2013-09-05

  The present application relates to novel substituted phenylacetamides and phenylpropanamides, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型取代苯乙酰胺和苯丙酰胺，以及用于制备它们的方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
  申请人：Galley Guido

  公开号：US20100120864A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X，Y，R1，R2和n如本文所定义，或其药学适宜的酸加盐。本发明还涉及含有此类化合物的制药组合物，以及用于治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍，应激相关障碍，精神疾病，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，物质滥用和代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和生物钟节律障碍以及心血管疾病。
• Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US08202895B2

  公开（公告）日：2012-06-19

  The present application relates to new, substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新的取代2-乙酰胺基-5-芳基-1,2,4-三唑酮，其制备过程，它们单独或联合用于治疗和/或预防疾病的用途，以及它们用于制造治疗和/或预防疾病的药物，更具体地用于治疗和/或预防心血管疾病。
• Substituted phenylacetate and phenylpropane amides and use thereof
  申请人：Fürstner Chantal

  公开号：US09034855B2

  公开（公告）日：2015-05-19

  The present application relates to novel substituted phenylacetamides and phenylpropanamides, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型取代苯乙酰胺和苯丙酰胺，以及制备它们的过程，它们单独或组合用于治疗和/或预防疾病，以及它们用于制造治疗和/或预防疾病的药物，更特别地用于治疗和/或预防心血管疾病。